The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection
Open accessAbstract
Introduction: The receptor for advanced glycation end products (RAGE), a multi-ligand member of the immunoglobulin superfamily, contributes to acute and chronic disease processes, including sepsis. Methods: We studied the possible therapeutic role of RAGE inhibition in the cecal ligation and puncture (CLP) model of polymicrobial sepsis and a model of systemic listeriosis using mice genetically deficient in RAGE expression or mice injected with a rat anti-murine RAGE monoclonal antibody. Results: The 7-day survival rates after CLP were 80% for RAGE-/- mice (n = 15) (P < 0.01 versus wild-type), 69% for RAGE+/- mice (n = 23), and 37% for wild-type mice (n = 27). Survival benefits were evident in BALB/c mice given anti-RAGE antibody (n = 15 per group) over serum-treated control animals (P < 0.05). Moreover, delayed treatment with anti-RAGE antibody up to 24 hours after CLP resulted in a significant survival benefit compared with control mice. There was no significant increase in tissue colony counts from enteric Gram-negative or Gram-positive bacteria in animals treated with anti-RAGE antibody. RAGE-/-, RAGE+/-, and anti-RAGE antibody-treated animals were resistant to lethality from Listeria monocytogenes by almost two orders of magnitude compared with wild-type mice. Conclusion: Further studies are warranted to determine the clinical utility of anti-RAGE antibody as a novel treatment for sepsis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin
Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25752 · Cited by 1,151
Rage and arthritis: The G82S polymorphism amplifies the inflammatory response
Hofmann, M. A., Drury, S., Hudson, B. I., Gleason, M. R., Qu, W., Lu, Y., Lalla, E., Chitnis, S., Monteiro, J., Stickland, M. H., et al. (2002) · Genes & Immunity · doi:10.1038/sj.gene.6363861 · Cited by 383
Bucciarelli, L. G., Wendt, T., Rong, L., Lalla, E., Hofmann, M. A., Goova, M. T., Taguchi, A., Yan, S. F., Yan, S. D., Stern, D. M., et al. (2002) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-002-8491-x · Cited by 304
Cited by
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437
HMGB1 and RAGE in Inflammation and Cancer
Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., & Coyle, A. J. (2010) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132603 · Cited by 1,436
Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?
Dejager, L., Pinheiro, I., Dejonckheere, E., & Libert, C. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.01.001 · Cited by 784
Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complications
Ramasamy, R., Yan, S. F., & Schmidt, A. M. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06320.x · Cited by 521
Alarmins: awaiting a clinical response
Chan, J. K., Roth, J., Oppenheim, J. J., Tracey, K. J., Vogl, T., Feldmann, M., Horwood, N., & Nanchahal, J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62423 · Cited by 511
Metadata
- Authors
- Lutterloh, E. C., Opal, S. M., Pittman, D. D., Keith, J. C., Tan, X.-Y., Clancy, B. M., Palmer, H., Milarski, K., Sun, Y., Palardy, J. E., Parejo, N. A., & Kessimian, N.
- Venue
- Critical Care
- Published
- 2007-11-06
- Volume
- 11
- Issue
- 6
- Pages
- R122-R122
- ISSN
- 1364-8535 (ISSN-L)
- OpenAlex
- W2130072278
- Cited by
- 168
- References
- 3
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.